CapitalBio Won 2007 State Scientific & Technological Award

CapitalBio Corporation announced that it received the second place of Technology Invention Award of 2007 State Scientific & Technological Award for its prestigious project titled "Development and Applications of Systematic Biochips and Related Equipment". This project was led by Dr. Jing Cheng, Chief Technology Officer of CapitalBio Corporation.  

Chinese President Hu Jintao, along with other senior Chinese leaders, presented the awards to scientists and entrepreneurs for their significant scientific contributions at the annual national science-technology award ceremony in the Great Hall of the People. Premier Wen Jiabao said in a keynote speech that China has reached a stage where it is more dependent on scientific and technological innovation than in the past, and it should strive to enhance its innovative capabilities, which is a national strategic priority. China started the national science and technology award system in 2000 to recognize those who have made outstanding achievements in scientific research and technological innovations, to encourage more scientists to make more breakthroughs in advancing China´s overall scientific and technological capabilities. The national government has set up five State Scientific and Technological Awards: the State Top Scientific and Technological Award, the State Natural Science Award, the State Technology Invention Award, the State Scientific and Technological Development Award and International Scientific and Technological Cooperation Award.

Headquartered in Beijing, China ,CapitalBio is a leading life science company that develops and commercializes total health-care solutions including a broad range of innovative biochip-related products for genomic and proteomic research, bio-safety test, clinical applications to address a wide range of human health needs. CapitalBio's project targets to improve people's livelihood and health, focusing on the prediction and prevention of diseases and the development of new treatment. Compared to traditional methods, biochip technology has many advantages, such as fast, multiple tests and inexpensive. It has great potential in life science and healthcare. The successful project has been carried out by a team of 73 scientists, led by Dr. Jing Cheng. Together, they have been awarded 19 international and domestic patents.

CapitalBio has to date developed and commercialized numerous advanced products such as microarray biochip readers or scanners, chip arrayers, related reagent kits, software for applications in discovery research, clinical diagnostics and biosafety testing. Many products have been widely adopted by Austria, Canada, Finland, France, Germany, Spain, Sweden, U.K., U.S., Thailand and Korea. Its broad and productive R&D programs have yielded over 60 issued patents from China, 20 from overseas, with more patents pending.